Curis reported Q3 2026 results highlighting progress on its lead oncology program emavusertib. The company announced an 86% response rate in BTK-naive patients with PCNSL (compared to 39-67% for BTK inhibitor monotherapy alone) and a 26% response rate in salvage-line patients. A CLL study was initiated with 12 patients enrolled across 11 sites, with initial data expected by year-end. The company reported a net loss of $8.1 million for Q3 2026 and $5 million in cash, with runway into 2027. Full enrollment in the PCNSL registrational study is expected by end of 2027, with NDA filing anticipated in 2028.